DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cannabinoid Receptor Type 1 (CB1) Antagonists - Pipeline Insights, 2017" drug pipelines to their offering.
Cannabinoid Receptor Type 1 (CB1) Antagonists - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Cannabinoid Receptor Type 1 (CB1) Antagonists. This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Cannabinoid Receptor Type 1 (CB1) Antagonists.
This report also assesses the Cannabinoid Receptor Type 1 (CB1) Antagonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.
Key Topics Covered:
- Cannabinoid Receptor Type 1 (CB1) Antagonists Overview
- Cannabinoid Receptor Type 1 (CB1) Antagonists Pipeline Therapeutics
- Cannabinoid Receptor Type 1 (CB1) Antagonists Therapeutics under Development by Companies
- Cannabinoid Receptor Type 1 (CB1) Antagonists Filed and Phase III Products
- Cannabinoid Receptor Type 1 (CB1) Antagonists Phase II Products
- Cannabinoid Receptor Type 1 (CB1) Antagonists Phase I and IND Filed Products
- Cannabinoid Receptor Type 1 (CB1) Antagonists Discovery and Pre-Clinical Stage Products
- Drug Candidate Profiles
- Cannabinoid Receptor Type 1 (CB1) Antagonists - Therapeutics Assessment
- Companies Involved in Therapeutics Development for Cannabinoid Receptor Type 1 (CB1) Antagonists
- Appendix
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/zvl5km/cannabinoid
